| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
5,366,000 |
| Market
Cap: |
7.83(M) |
| Last
Volume: |
140,704 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.506 - $1.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company focused on developing cancer immunotherapeutics for a range of cancer indications. Co.'s product candidates include galinpepimut-S (GPS) and nelipepimut-S (NPS). Co.'s primary product candidate, GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets the Wilms tumor 1 protein, which is present in 20 or more cancer types. NPS is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 expressing cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
9,806 |
| Total Sell Value |
$0 |
$0 |
$0 |
$25,516 |
| Total People Sold |
0 |
0 |
0 |
3 |
| Total Sell Transactions |
0 |
0 |
0 |
3 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Nisi Rudolph |
Director |
– • – |
2017-01-20 |
4 |
A |
$1.98 |
$6,459 |
D/D |
3,262 |
4,437 |
|
- |
|
| Galliker Stephens S |
Director |
– • – |
2017-01-20 |
4 |
A |
$1.98 |
$6,041 |
D/D |
3,051 |
3,551 |
|
- |
|
| Nejadnik Bijan |
Chief Medical Officer |
• – – |
2016-07-01 |
4 |
A |
$0.40 |
$3,397 |
D/D |
8,503 |
8,503 |
|
- |
|
| Burns John Thomas |
Principal Accounting Officer |
• – – |
2016-07-01 |
4 |
A |
$0.40 |
$3,397 |
D/D |
8,503 |
10,899 |
|
- |
|
| Schwartz Mark W. |
President & CEO |
• – – |
2016-07-01 |
4 |
A |
$0.40 |
$3,397 |
D/D |
8,503 |
439,978 |
|
- |
|
| Dunlap Ryan |
Former Chief Financial Officer |
• – – |
2016-06-01 |
4 |
S |
$2.18 |
$276,588 |
D/D |
(126,875) |
18,702 |
|
- |
|
| Dunlap Ryan |
Former Chief Financial Officer |
• – – |
2016-06-01 |
4 |
OE |
$1.71 |
$227,394 |
D/D |
126,875 |
145,577 |
|
- |
|
| Gray Mary Ann |
Director |
– • – |
2016-04-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
39,938 |
|
- |
|
| Burns John Thomas |
Principal Accounting OfficerOf |
• – – |
2016-02-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,396 |
|
- |
|
| Schwartz Mark W. |
President & CEO |
• • – |
2014-12-31 |
4 |
A |
$1.28 |
$4,923 |
D/D |
3,846 |
415,972 |
|
- |
|
| Dunlap Ryan |
VP, Chief Financial Officer |
• – – |
2014-12-31 |
4 |
A |
$1.28 |
$4,923 |
D/D |
3,846 |
11,650 |
|
- |
|
| Schwartz Mark W. |
EVP, Chief Operating Officer |
• – – |
2014-06-30 |
4 |
A |
$2.60 |
$6,399 |
D/D |
2,461 |
412,126 |
|
- |
|
| Hamilton Brian L |
EVP, Chief Medical Officer |
• – – |
2014-06-30 |
4 |
A |
$2.60 |
$6,399 |
D/D |
2,461 |
2,461 |
|
- |
|
| Dunlap Ryan |
VP, Chief Financial Officer |
• – – |
2014-06-30 |
4 |
A |
$2.60 |
$6,399 |
D/D |
2,461 |
7,804 |
|
- |
|
| Ahn Mark J |
President & CEO |
• • – |
2014-06-30 |
4 |
A |
$2.60 |
$6,399 |
D/D |
2,461 |
116,225 |
|
- |
|
90 Records found
|
|
Page 4 of 4 |
|
|
0.01 (0.68%) 
